Gut Microbiota, Deranged Immunity, and Hepatocellular Carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) Pathogenesis
• Gastrointestinal Oncology
• Immunotherapy Biomarkers

Background:

• Hepatocellular carcinoma (HCC) presents a high mortality rate, linked to immune dysregulation and altered bile acid metabolism.
• The gut microbiota (GM) significantly influences HCC development and response to treatments like immune checkpoint inhibitors (ICIs).
• Current limitations in ICI efficacy for HCC stem from a lack of predictive biomarkers.

Purpose of the Study:

• To review literature on HCC treatment, emphasizing the roles of the immune system, bile acid metabolism, and gut microbiota dysbiosis.
• To identify potential biomarkers for predicting response to immune checkpoint inhibitors in liver cancer patients.

Main Methods:

• Literature search of PubMed, Medline, and major gastroenterology/hepatology conference proceedings.
• Keywords included: gut microbiota, immune system, liver cancer, and checkpoint inhibitors.

Main Results:

• Gut microbiota dysbiosis is strongly associated with altered immune responses and bile acid metabolism in HCC.
• Gut microbiota composition shows potential as a biomarker for predicting ICI response in liver cancer.
• Interventions targeting the gut microbiota may enhance the efficacy of ICI therapy for HCC.

Conclusions:

• Gut microbiota dysbiosis is a critical factor in liver cancer pathogenesis and influences treatment outcomes.
• Modulating the gut microbiota offers a promising strategy for improving HCC prognosis and immunotherapy response.
• Further research is needed to establish direct therapeutic benefits of GM modulation in HCC.